130 related articles for article (PubMed ID: 25625274)
1. Nuclear osteopontin-c is a prognostic breast cancer marker.
Zduniak K; Ziolkowski P; Ahlin C; Agrawal A; Agrawal S; Blomqvist C; Fjällskog ML; Weber GF
Br J Cancer; 2015 Feb; 112(4):729-38. PubMed ID: 25625274
[TBL] [Abstract][Full Text] [Related]
2. Osteopontin-c is a selective marker of breast cancer.
Mirza M; Shaughnessy E; Hurley JK; Vanpatten KA; Pestano GA; He B; Weber GF
Int J Cancer; 2008 Feb; 122(4):889-97. PubMed ID: 17960616
[TBL] [Abstract][Full Text] [Related]
3. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin splice variants are differential predictors of breast cancer treatment responses.
Zduniak K; Agrawal A; Agrawal S; Hossain MM; Ziolkowski P; Weber GF
BMC Cancer; 2016 Jul; 16():441. PubMed ID: 27400751
[TBL] [Abstract][Full Text] [Related]
5. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.
Niméus-Malmström E; Koliadi A; Ahlin C; Holmqvist M; Holmberg L; Amini RM; Jirström K; Wärnberg F; Blomqvist C; Fernö M; Fjällskog ML
Int J Cancer; 2010 Aug; 127(4):961-7. PubMed ID: 19957331
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
7. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
[TBL] [Abstract][Full Text] [Related]
8. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
9. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
Zhang R; Zhang H; Wei H; Luo X
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
[TBL] [Abstract][Full Text] [Related]
10. Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer.
Ditsch N; Toth B; Himsl I; Lenhard M; Ochsenkühn R; Friese K; Mayr D; Jeschke U
Histol Histopathol; 2013 Feb; 28(2):227-37. PubMed ID: 23275305
[TBL] [Abstract][Full Text] [Related]
11. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer risk in premalignant lesions: osteopontin splice variants indicate prognosis.
Walaszek K; Lower EE; Ziolkowski P; Weber GF
Br J Cancer; 2018 Nov; 119(10):1259-1266. PubMed ID: 30353046
[TBL] [Abstract][Full Text] [Related]
13. St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
Falck AK; Röme A; Fernö M; Olsson H; Chebil G; Bendahl PO; Rydén L
Br J Surg; 2016 Apr; 103(5):513-23. PubMed ID: 26856820
[TBL] [Abstract][Full Text] [Related]
14. Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma.
Laurinavicius A; Green AR; Laurinaviciene A; Smailyte G; Ostapenko V; Meskauskas R; Ellis IO
Oncotarget; 2015 Dec; 6(38):41134-45. PubMed ID: 26512778
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype.
Mylona E; Tzelepis K; Theohari I; Giannopoulou I; Papadimitriou C; Nakopoulou L
Histopathology; 2013 Feb; 62(3):472-80. PubMed ID: 23163571
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma.
Karray-Chouayekh S; Baccouche S; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
Acta Histochem; 2011 Sep; 113(5):508-13. PubMed ID: 20598349
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters.
Ravikumar G; Ananthamurthy A
J Cancer Res Ther; 2014; 10(3):671-5. PubMed ID: 25313758
[TBL] [Abstract][Full Text] [Related]
18. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
Voduc D; Nielsen TO; Cheang MC; Foulkes WD
Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study.
Lundgren C; Ahlin C; Holmberg L; Amini RM; Fjällskog ML; Blomqvist C
Acta Oncol; 2015 Apr; 54(4):538-44. PubMed ID: 25327158
[TBL] [Abstract][Full Text] [Related]
20. Expression of 6 common antigenic markers in invasive ductal breast carcinoma: potential clinical implications.
Lialiaris TS; Kouskoukis A; Georgiou G; Tripsianis G; Fiska A; Giatromanolaki A; Chrisafi S; Sivridis E; Vamvakopoulou DN; Soutopoulou DO; Kiritsaka A; Athanassiou E; Lialios GA; Sotiriou S; Sidiropoulos A; Vamvakopoulos NC
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):106-11. PubMed ID: 20724920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
